Mustang Bio, Inc.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company specializing in cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases. The company's pipeline includes gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. Its revenue is generated through the development and commercialization of these innovative therapies, including MB-107 and MB-207 for X-linked severe combined immunodeficiency, and various CAR T cell programs targeting different types of cancers.

Products

• Gene therapy programs for rare genetic disorders

• CAR T therapies for hematologic malignancies and solid tumors